Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

86.60 1.50 −1.70%
Market cap
$50.8B
P/E
49.8×
Fwd P/E
30.7×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a

Edwards Lifesciences Corporation 10-K filed Feb 25, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:11 PM ET · Document on sec.gov · Filing index

What changed

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 28, 2025: 15 added · 36 removed · 42 modified; 9 with only figures updated; 2 moved without change

93 more changes in this Item, word by word, in Powerpack.

Powerpack